We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+1.34%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$42.2B
AUM Growth
-$1.23B
(-2.8%)
Cap. Flow
-$952M
Cap. Flow
% of AUM
-2.26%
Top 10 Holdings %
Top 10 Hldgs %
14.57%
Holding
2,171
New
150
Increased
772
Reduced
960
Closed
152
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$156M |
| 2 |
Prologis
PLD
|
+$150M |
| 3 |
Chevron
CVX
|
+$109M |
| 4 |
Qualcomm
QCOM
|
+$101M |
| 5 |
Paycom
PAYC
|
+$90.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$230M |
| 2 |
Kimberly-Clark
KMB
|
+$160M |
| 3 |
Stanley Black & Decker
SWK
|
+$130M |
| 4 |
Paychex
PAYX
|
+$113M |
| 5 |
Dominion Energy
D
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.81% |
| 2 | Healthcare | 17.11% |
| 3 | Financials | 12.73% |
| 4 | Industrials | 9.87% |
| 5 | Consumer Discretionary | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1851
Trinity Industries
TRN
$2.24B
| $4.49K | ﹤0.01% |
150
| – | – |
|
1852
Byrna Technologies
BYRN
$87.3M
| $4.41K | ﹤0.01% |
442
+285
| +182% | +$3.51K |
|
1853
First Bancorp
FBP
$4.29B
| $4.41K | ﹤0.01% |
241
-3
| -1% | -$53 |
|
1854
AudioEye
AEYE
$92.8M
| $4.19K | ﹤0.01% |
238
+75
| +46% | +$1.32K |
|
1855
Prudential
PUK
$32.8B
| $4.16K | ﹤0.01% |
227
| – | – |
|
1856
Honda
HMC
$41.8B
| $4.13K | ﹤0.01% |
128
| – | – |
|
1857
Lucid Motors
LCID
$1.62B
| $4.12K | ﹤0.01% |
158
-13
| -8% | -$347 |
|
|
ORGN
1858
DELISTED
Origin Materials
ORGN
| $4.11K | ﹤0.01% |
152
-439
| -74% | -$11.7K |
|
1859
Barrett Business Services
BBSI
$820M
| $4.06K | ﹤0.01% |
124
-8
| -6% | -$253 |
|
1860
Organogenesis Holdings
ORGO
$188M
| $4.05K | ﹤0.01% |
1,447
-9,243
| -86% | -$24.8K |
|
1861
Smart Sand
SND
$219M
| $3.91K | ﹤0.01% |
1,852
-168
| -8% | -$357 |
|
1862
Foster
FSTR
$392M
| $3.87K | ﹤0.01% |
180
+16
| +10% | +$412 |
|
1863
Rentokil
RTO
$11.2B
| $3.83K | ﹤0.01% |
129
| – | – |
|
1864
Andersons Inc
ANDE
$2.42B
| $3.82K | ﹤0.01% |
77
+2
| +3% | +$107 |
|
1865
ING
ING
$105B
| $3.65K | ﹤0.01% |
213
| – | – |
|
1866
Vor Biopharma
VOR
$1.32B
| $3.6K | ﹤0.01% |
+180
| New | +$5.82K |
|
1867
Porch Group
PRCH
$1.82B
| $3.6K | ﹤0.01% |
2,383
+815
| +52% | +$2.27K |
|
1868
Compass Therapeutics
CMPX
$333M
| $3.59K | ﹤0.01% |
3,592
+2,659
| +285% | +$3.88K |
|
1869
Goldgroup Mining
GORO
$477M
| $3.58K | ﹤0.01% |
2,393
| – | – |
|
1870
QuantumScape Corp
QS
$3.11B
| $3.52K | ﹤0.01% |
715
-59
| -8% | -$329 |
|
|
EARN
1871
Ellington Residential Mortgage REIT
EARN
$156M
| $3.46K | ﹤0.01% |
498
| – | – |
|
1872
F&G Annuities & Life
FG
$3.08B
| $3.42K | ﹤0.01% |
+90
| New | +$3.53K |
|
|
PARA
1873
DELISTED
Paramount Global Class B
PARA
| $3.4K | ﹤0.01% |
327
-1,292
| -80% | -$15.1K |
|
1874
Vitamin Cottage Natural Grocers
NGVC
$665M
| $3.24K | ﹤0.01% |
153
-53
| -26% | -$1.01K |
|
|
TVRD
1875
Tvardi Therapeutics
TVRD
$23.5M
| $3.13K | ﹤0.01% |
338
-3
| -0.9% | -$72 |
|
Similar funds
Federated Hermes's Q2 2024 Portfolio in Review
As of Q2 2024, Federated Hermes held 2,171 positions worth $42.2B, down 2.8% from $43.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes's Q2 2024 filing shows 150 new, 772 increased, 960 reduced and 152 closed positions. Its largest new stake was Loar Holdings: 729,296 shares worth $39M. The largest sale was Fusion Pharmaceuticals Inc. Common Shares, an estimated $230M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.
- Federated Hermes's largest Q2 2024 buy was Loar Holdings: 729,296 shares worth $39M.
- Federated Hermes added most to Bristol-Myers Squibb in Q2 2024, an estimated $156M increase.
- Federated Hermes's biggest Q2 2024 reduction was Kimberly-Clark, cutting an estimated $160M.
- Federated Hermes fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $230M.
- Federated Hermes's ten largest holdings make up 15% of its $42.2B portfolio in Q2 2024.
- Federated Hermes opened 150 new positions and closed 152 in Q2 2024.
- Federated Hermes's portfolio value fell 2.8% quarter-over-quarter to $42.2B.
Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.